Pyridoxamine, advanced glycation inhibition, and diabetic nephropathy

Journal of the American Society of Nephrology

Volumn 23, Issue 1, 2012, Pages 6-8

  Chen, Joline L T ^a   Francis, Jean ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; AVOSENTAN; BARDOXOLONE METHYL; CREATININE; CYSTATIN C; ENDOTHELIN; INSULIN RECEPTOR; IRBESARTAN; PIRFENIDONE; PLACEBO; PYRIDORIN; PYRIDOXAMINE; SULODEXIDE; THIAMINE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ALBUMINURIA; BLOOD PRESSURE REGULATION; CHRONIC INFLAMMATION; COMPETITIVE INHIBITION; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DRUG EFFICACY; EDITORIAL; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; MACROALBUMINURIA; MESANGIUM CELL; MOLECULAR PATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PODOCYTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION;

EID: 84862928624     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2011111097     Document Type: Editorial

References (23)

1. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001
2. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 355: 253-259, 2000
3. U.S. Renal Data System: USRDS 2011 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2011
4. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
5. Sarafidis PA, Stafylas PC, Georgianos PI, Saratzis AN, Lasaridis AN: Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: A meta-analysis. Am J Kidney Dis 55: 835-847, 2010
6. Welsh GI, Hale LJ, Eremina V, Jeansson M, Maezawa Y, Lennon R, Pons DA, Owen RJ, Satchell SC, Miles MJ, Caunt CJ, McArdle CA, Pavenstädt H, Tavaré JM, Herzenberg AM, Kahn CR, Mathieson PW, Quaggin SE, Saleem MA, Coward RJ: Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab 12: 329-340, 2010
7. Brezniceanu ML, Lau CJ, Godin N, Chénier I, Duclos A, Ethier J, Filep JG, Ingelfinger JR, Zhang SL, Chan JS: Reactive oxygen species promote caspase-12 expression and tubular apoptosis in diabetic nephropathy. J Am Soc Nephrol 21: 943-954, 2010
8. Yi X, Xu L, Hiller S, Kim HS, Nickeleit V, James LR, Maeda N: Reduced expression of lipoic acid synthase accelerates diabetic nephropathy [published online ahead of print October 21, 2011]. J Am Soc Nephrol doi: 10.1681/ASN.2011010003
9. Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB, Krauth M, Ruiz S, Audhya P, Christ-Schmidt H, Wittes J, Warnock DG; BEAM Study Investigators: Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365: 327-336, 2011
10. Sharma K, Ix JH, Mathew AV, Cho M, Pflueger A, Dunn SR, Francos B, Sharma S, Falkner B, McGowan TA, Donohue M, Ramachandrarao S, Xu R, Fervenza FC, Kopp JB: Pirfenidone for diabetic nephropathy. J Am Soc Nephrol 22: 1144-1151, 2011
11. Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G; ASCEND Study Group: Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 21: 527-535, 2010
12. Packham DK, Wolfe R, Reutens AT, Berl T, Heerspink HL, Rohde R, Ivory S, Lewis J, Raz I, Wiegmann TB, Chan JC, de Zeeuw D, Lewis EJ, Atkins RC: Sulodexide fails to demonstrate renoprotection renoprotectionin overt type 2 diabetic nephropathy [published online ahead of print October 27, 2011]. J Am Soc Nephrol doi: 10.1681/ASN.2011040378
13. Lewis EJ, Lewis JB, Greene T, Hunsicker LG, Berl T, Pohl MA, de Zeeuw D, Heerspink HL, Rohde RD, Atkins RC, Reutens AT, Packham DK, Raz I; Collaborative Study Group: Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis 58: 729-736, 2011
14. Bohlender JM, Franke S, Stein G, Wolf G: Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 289: F645-F659, 2005 (Pubitemid 41324185)
15. Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, Striker LJ: Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci USA 91: 9436-9440, 1994 (Pubitemid 24297929)
16. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, Stein G, Bierhaus A, Liliensiek B, Arnold B, Nawroth PP, Stern DM, D'Agati VD, Schmidt AM: RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 162: 1123-1137, 2003 (Pubitemid 36350658)
17. Sourris KC, Forbes JM, Cooper ME: Therapeutic interruption of advanced glycation in diabetic nephropathy: Do all roads lead to Rome? Ann N Y Acad Sci 1126: 101-106, 2008 (Pubitemid 351589310)
18. Turgut F, Bolton WK: Potential new therapeutic agents for diabetic kidney disease. Am J Kidney Dis 55: 928-940, 2010
19. Degenhardt TP, Alderson NL, Arrington DD, Beattie RJ, Basgen JM, Steffes MW, Thorpe SR, Baynes JW: Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61: 939-950, 2002 (Pubitemid 34175462)
20. Tanimoto M, Gohda T, Kaneko S, Hagiwara S, Murakoshi M, Aoki T, Yamada K, Ito T, Matsumoto M, Horikoshi S, Tomino Y: Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice. Metabolism 56: 160-167, 2007 (Pubitemid 46074060)
21. Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB: Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol 27: 605-614, 2007 (Pubitemid 350014947)
22. Lewis EJ, Greene T, Spitalewiz S, Blumenthal S, Berl T, Hunsicker LG, Pohl MA, Rohde RD, Raz I, Yerushalmy Y, Yagil Y, Herskovits T, Atkins RC, Reutens AT, Packham DK, Lewis JB: Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol, 23:131-136, 2012
23. Fioretto P, Mauer M: Histopathology of diabetic nephropathy. Semin Nephrol 27: 195-207, 2007 (Pubitemid 46550314)